Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab and TKI for Ph+ ALL
NCT04329325Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2020
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Complete Molecular Response at 7 months. Started Mar 2020; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT04329325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329325.